|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.920 USD | -3.22% |
|
+23.13% | -4.02% |
| 05-23 | Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025 | |
| 05-19 | Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder | RE |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 20K | -475,295% | -515,860% | -59.84% | - | 1.28x | ||
| 14.2B | 31.07% | 36.33% | 19.23% | 15.02% | -1.12x | ||
| 2.22B | 36.99% | -0.96% | 2.26% | 2.02% | 234.49x | ||
| 3.81B | -16.92% | -14.91% | -18.77% | -11% | 4.06x | ||
| 5.38B | 24.08% | 29.51% | 16.78% | 12.27% | -0.97x | ||
| 2.85B | -24.18% | -47.77% | -3.3% | -2.88% | 9.36x | ||
| 364M | -251.24% | -241.47% | -1,601.19% | -54.47% | 0.16x | ||
| 2.56B | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | ||
| 2.99B | 36.44% | 32.53% | 22.97% | 19.34% | -2.97x | ||
| 2.17B | 24.04% | 27.88% | 23.13% | 17.7% | -1.75x | ||
| 291M | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | ||
| 265M | -13.8% | -7.18% | -9.46% | -9.11% | 3.86x | ||
| 41.93M | -410.18% | -365.73% | - | - | - | ||
| 627M | -28.22% | -21.76% | -15.45% | -10.06% | 13.02x | ||
| 180M | -258.64% | -276.39% | -80.35% | - | 1.63x | ||
| 297M | 30.46% | 17.83% | 7.52% | 6.63% | -9.98x | ||
| 487M | 40.03% | 45.91% | 30.74% | 24.08% | - | ||
| Average | 2.28B | -28,004.78% | -30,391.01% | -103.94% | 0.95% | 16.51x | |
| Weighted average by Cap. | 4.61B | -932.68% | -1,013.32% | -101.97% | 1.24% | 30.83x |
- Stock Market
- Equities
- ALT Stock
- Sector Altimmune, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition